<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673606</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000496</org_study_id>
    <nct_id>NCT02673606</nct_id>
  </id_info>
  <brief_title>Impact of Estrogen on Fear Extinction R61</brief_title>
  <official_title>The Influence of Estrogen on the Fear Extinction Network in Humans-R61</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to examine how estrogen may influence the resting-state
      connectivity and the extinction-induced activation of the fear extinction network.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study was to examine the influence of exogenous estrogen administration on the
      activation of the fear extinction network in women. Functional MRI data and
      psychophysiological indices were collected to test the influence of estrogen on women's
      ability to regulate conditioned fear responses. Women underwent a 3 day experimental paradigm
      using classical fear conditioning. The first day was conducted outside the scanner, while
      days 2 and 3 were done inside the fMRI scanner and tested fear extinction learning and recall
      in days 2 and 3, respectively. The estrogen (or placebo) pill was given just hours before
      extinction learning test on day 2. No followups were conducted after women completed the 3
      day study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind placebo control study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of exogenous administration of estradiol on the neural correlates of fear extinction</measure>
    <time_frame>3 Days</time_frame>
    <description>BOLD responses during fear extinction after taking estradiol or placebo</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Fear</condition>
  <condition>Fear; Examination, Phobic</condition>
  <arm_group>
    <arm_group_label>Estradiol 2mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg dose of estradiol (oral administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol 4mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg dose of estradiol (oral administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (oral administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 2Mg Tablet</intervention_name>
    <description>one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),</description>
    <arm_group_label>Estradiol 2mg Dose</arm_group_label>
    <other_name>Estrace® Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 4Mg Tablet</intervention_name>
    <description>two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),</description>
    <arm_group_label>Estradiol 4mg Dose</arm_group_label>
    <other_name>Estrace® Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Pills</intervention_name>
    <description>inactive placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Estrace® Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Right-handed (Edinburgh Inventory - Oldfield 1971).

          -  SCID diagnosis consistent with none, current or past history of Axis I psychiatric
             disorders.

          -  To be matched for age, gender, and years of education, as well as self-identified
             race/ethnicity.

          -  For naturally cycling female subjects, stage of menstrual cycle will be ascertained by
             history, and by serological measures.

          -  For women on oral contraceptives, we will identify those using 20mcg ethinyl, 2nd or
             3rd generation, monophasic

        Exclusion Criteria:

          -  Psychiatric, neurologic or medical condition that would interfere with study
             procedures or confound results, ascertained by history.

          -  History of seizure or significant head trauma (i.e., extended loss of consciousness,
             neurological sequelae, or known structural brain lesion).

          -  History of Axis I psychiatric diagnosis; e.g., history of substance use disorder,
             psychotic disorder, bipolar disorder, tic disorder, or eating disorder.

          -  Use of psychotropic medication within 4 weeks prior to study (within 6 weeks for
             fluoxetine, or other long-lived compounds; within one year for neuroleptics).

          -  Pregnancy (to be ruled out by urine ß-HCG).

          -  Metallic implants or devices contraindicating magnetic resonance imaging.

          -  Use of oral contraceptives or non-oral contraceptives containing estrogen and
             progesterone within 3 months

          -  History of breast cancer.

          -  Allergy to peanut oil.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Milad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

